Study of the Efficacy of Maintenance Therapy Using Uracil-tegafur (UFT) or Bacille Calmette-Guerin (BCG) for the Prevention of Recurrences of Superficial Bladder Cancer (EMBARK Study)

  • participants needed
  • sponsor
    Urological Oncology Council of Northern Tokyo
Updated on 8 November 2020
bladder cancer
transurethral resection
bladder tumor
transurethral bladder excision
superficial bladder cancer
intravesical administration


The purpose of this prospective randomized controlled study is to prove the non-inferiority of UFT maintenance therapy to BCG maintenance therapy for preventing recurrences of superficial bladder cancer.


Patients who have undergone transurethral resection of a superficial bladder tumor (TUR-Bt) and BCG induction therapy are eligible for enrollment in this study. In principle, BCG induction therapy consists of the successive weekly intravesical administration of 81 mg of BCG-Connaught strain or 80 mg of BCG-Japan strain for 6 weeks after the completion of TUR-Bt.

The patients will be randomly assigned to a BCG maintenance therapy arm or a UFT maintenance therapy arm. The patients in the BCG maintenance therapy arm will be treated with 3 successive weekly intravesical administrations of BCG at 3, 6, 12 and 18 months after the start of BCG induction therapy. The dosage of BCG used for BCG maintenance therapy will be the same as that used for BCG induction therapy. Patients in the UFT maintenance therapy arm will be treated with the oral administration of 400 mg of UFT everyday for three years after the end of BCG induction therapy.

The primary endpoint of this study is the three-year relapse-free survival rate.

Condition bladder cancer
Treatment Bacille Calmette-Guérin, uracil-tegafur
Clinical Study IdentifierNCT01082510
SponsorUrological Oncology Council of Northern Tokyo
Last Modified on8 November 2020


Yes No Not Sure

Inclusion Criteria

Is your age between 20 yrs and 80 yrs?
Gender: Male or Female
Do you have bladder cancer?
Superficial bladder cancer
Completion of transurethral resection of bladder tumor (TUR-Bt)
Completion of BCG induction therapy after TUR-Bt. In principle, BCG induction therapy consists of the successive weekly intravesical administration of 81 mg of BCG-Connaught strain or 80 mg of BCG-Japan strain for 6 weeks after the completion of TUR-Bt
Age 20 to 80 years
ECOG performance status of 0 or 1
Bladder capacity 150 mL
Capable of oral UFT administration
Expected life prognosis 3 years
Hematopoietic WBC 3,000/mm^3
Neutrophil 1,500/mm^3
Platelet 100,000/mm^3
Hepatic AST and ALT 2 times upper limit of normal (ULN)
Total bilirubin 1.5 mg/dL
Hemoglobin 9.0 g/dL
Creatinine 1.5 mg/dL

Exclusion Criteria

Bladder cancer located in prostatic part of the urethra
Anamnesis of bladder cancer classified as cT2, cT3 or cT4
Anamnesis of metastatic bladder cancer
Anamnesis of upper urinary tract carcinoma in situ
Anamnestic treatment of intravesical BCG administration within previous 6 months
Prior anticancer chemotherapy or radiotherapy
Severe complication
Presence of contraindications for the administration of BCG or UFT
Pregnancy, lactation
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note